Pluri Inc./$PLUR
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Pluri Inc.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.
- Ticker
- $PLUR
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 103
- Headquarters
- Haifa, Israel
- Website
- www.pluri-biotech.com
Pluri Inc. Metrics
BasicAdvanced
$15M
-
-$2.44
0.68
-
Price and volume
Market cap
$15M
Beta
0.68
52-week high
$4.87
52-week low
$0.85
Average daily volume
50K
Financial strength
Current ratio
0.267
Quick ratio
0.245
Long term debt to equity
-0.372
Total debt to equity
-2.003
Interest coverage (TTM)
-26.76%
Profitability
EBITDA (TTM)
-24.427
Gross margin (TTM)
44.59%
Net profit margin (TTM)
-2,344.59%
Operating margin (TTM)
-2,454.53%
Effective tax rate (TTM)
0.10%
Revenue per employee (TTM)
$10,000
Management effectiveness
Return on assets (TTM)
-49.04%
Return on equity (TTM)
277.27%
Valuation
Price to revenue (TTM)
11.509
Price to book
-0.56
Price to tangible book (TTM)
-0.45
Price to free cash flow (TTM)
-0.578
Free cash flow yield (TTM)
-172.94%
Free cash flow per share (TTM)
-2.075
Growth
Revenue change (TTM)
-23.95%
Earnings per share change (TTM)
-31.40%
3-year revenue growth (CAGR)
52.41%
10-year revenue growth (CAGR)
-9.79%
3-year earnings per share growth (CAGR)
-26.60%
10-year earnings per share growth (CAGR)
-20.21%
Pluri Inc. Financial Performance
Revenues and expenses
Pluri Inc. Earnings Performance
Company profitability
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.